A selection of must-have articles
Pulmonary Aterial Hypertension
Upregulated Genes In Sporadic, Idiopathic Pulmonary Arterial Hypertension
To elucidate further the pathogenesis of sporadic, idiopathic pulmonary arterial
hypertension (IPAH) and identify potential therapeutic avenues, differential gene expression in
IPAH was examined by suppression subtractive hybridisation (SSH).
Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension
The effects of pulmonary arterial hypertension on cardiovascular and physical function are well documented. Limited information exists regarding the effects of pulmonary arterial hypertension on cognitive function.
Beyond Trial Registration: A Global Trial Bank for Clinical Trial Reporting
Clinical trials are one of the most valuable sources of evidence to determine which therapies are safe and effective. However, instances of selective reporting of results to benefit proprietary interests rather than public health have recently come to light.
Keeping you up to date with the latest clinical trial information
REVEAL Registry™: Registry to Evaluate Early And Long-Term PAH Disease Management
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrolment.
Related Articles
Keeping you up to date with the latest clinical trial information
To Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of PAH
To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.
Related Articles
Keeping you up to date with the latest clinical trial information
Effects of Combination of Bosentan and Sildenafil Vs Sildenafil Monotherapy on PAH
This study will investigate the effects of the combination of bosentan and sildenafil. This approach appears as a
highly attractive therapeutic option to address the multiple pathophysiological mechanisms that are present in PAH.
Several advantages are obvious: both substances are orally available and both are usually well tolerated. In addition,
bosentan and sildenafil have different mechanisms of action, aiming at different intracellular targets. This implies
that combination therapy is likely to result in synergistic effects. It will be the first event-driven study in PAH ever
conducted.
Related Articles
Treatment for: Pulmonary Arterial Hypertension